From gene therapy and stem cells to clinical electrophysiology.
Gene therapy, cell therapy, and tissue engineering are emerging as novel experimental therapeutic paradigms for a variety of cardiovascular disorders. In the current report we will review the possible implications of these emerging technologies in the field of cardiac electrophysiology. Initially, the possible role of myocardial gene and cell therapies in creating a biological alternative to electronic pacemakers for the treatment of bradyarrhythmias will be discussed. This will be followed by a description of the possible applications of using similar strategies for the treatment of common tachyarrhythmias. Finally, the electrophysiological implications of cardiac stem cell therapy for heart failure, as well as the possible in vitro applications of stem cell technology for electrophysiological studies and drug screening, will be discussed. While these emerging strategies provide a paradigm shift from conventional treatment modalities, this field is still at its infancy and several obstacles, discussed in this review, should be overcome before any clinical breakthroughs can be expected.
Yankelson
Lior
L
Sohnis Family Research Laboratory for the Regeneration of Functional Myocardium, Department of Biophysics and Physiology, the Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Gepstein
Lior
L
D000818:Animals; D002304:Cardiac Pacing, Artificial / Q000639:trends*; D002318:Cardiovascular Diseases / Q000628:therapy*; D022062:Electrophysiologic Techniques, Cardiac / Q000639:trends*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D033581:Stem Cell Transplantation / Q000639:trends*; D023822:Tissue Engineering / Q000639:trends*